NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab (NCT04211675)
A Phase I/II Safety Lead in Study of Ex-Vivo Expanded Allogeneic Universal Donor TGFฮฒi NK Cell Infusions in Combination With Irinotecan, Temozolomide, and Dinutuximab in Patients With Relapsed or Refractory Neuroblastoma: The Allo - STING Trial
๐ฉบ Plain-English Summary (8th-Grade Level)
This is a Phase 1 study with Phase 2 expansion cohort. Phase 1 will assess the safety and tolerability of universal donor TGFฮฒi NK Cell in combination with irinotecan, temozolomide, and dinituximab. The phase 2 of the study will estimate the response to treatment.
Who can join: Review the eligibility criteria below.
Location: Nationwide Children's Hospital โ Columbus, Ohio
Age range: Not specified to 29 Years
๐งช Interventions in This Study
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (1 Sites)
- Nationwide Children's Hospital โ Columbus, Ohio
๐ Contact the Study Coordinator
Phone: (614) 722-6039
Email: Melinda.Triplet@nationwidechildrens.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Relapsed Neuroblastoma
- Parental Decision-Making for Children With Relapsed Neuroblastoma โ Los Angeles, California
- C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) โ Houston, Texas
- NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma โ Houston, Texas
- Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma โ Boston, Massachusetts
Explore by condition: All Relapsed Neuroblastoma clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.